Clinical trials: Relapsed/Refractory Peripheral T-cell Lymphoma
- Condition Relapsed/Refractory Peripheral T-cell Lymphoma
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Hematologic Malignancies, Solid Tumor
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Multicenter, open-label, phase 1a/1b trial of PF-07901800 (TTI-621) in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.
- Trial name
- NCT02663518
- Testing
- PF-0791800 (TTI-621), PF-07901800 (TTI-621) plus Rituximab, PF-07901800 (TTI-621) plus Nivolumab
- Where
- 51 sites in United States, Canada
- Volunteers
- 249 people
- Sponsor
- Pfizer
T-cell Non-Hodgkin's Lymphoma
A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma
This is a Phase II, multicenter, single-arm, open-label study of oral lenalidomide monotherapy administered to subjects with relapsed or refractory T-cell lymphoma.
- Trial name
- EXPECT (NCT00655668)
- Testing
- Lenalidomide
- Where
- 45 sites in United States, Australia and 2 more
- Volunteers
- 54 people
- Sponsor
- Celgene
Peripheral T Cell Lymphoma, Transformed Mycosis Fungoides
Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides
This is a phase II study to evaluate the antitumor activity and safety of AFM13 given as monotherapy in patients with CD30-positive T-cell lymphoma.
- Trial name
- REDIRECT (NCT04101331)
- Testing
- AFM13
- Where
- 69 sites in United States, Australia and 8 more
- Volunteers
- 108 people
- Sponsor
- Affimed GmbH
Relapsed or Refractory Peripheral T Cell Lymphoma
Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)
This is a multinational, non-randomized, open-label, Phase 1/2 clinical study to evaluate the safety, tolerability and anti-tumor efficacy of AZD4205 as monotherapy in patients with peripheral T cell lymphoma (PTCL), who have…
- Trial name
- NCT04105010
- Testing
- golidocitinib
- Where
- 50 sites in United States, Australia and 2 more
- Volunteers
- 171 people
- Sponsor
- Dizal Pharmaceuticals
Relapsed or Refractory Peripheral T-Cell Lymphoma
Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy
Phase II study designed to investigate antitumor activity in terms of objective response rate (ORR) of tipifarnib subjects with advanced Peripheral T-Cell Lymphoma (PTCL).
- Trial name
- PTCL (NCT02464228)
- Testing
- Tipifarnib
- Where
- 13 sites in United States, South Korea and 1 more
- Volunteers
- 65 people
- Sponsor
- Kura Oncology, Inc.
Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Cutaneous
Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma
The purpose of this study is to evaluate the safety, PK and efficacy of RP6530, a dual PI3K delta/gamma inhibitor in patients with relapsed and refractory T-cell Lymphoma.
- Trial name
- NCT02567656
- Testing
- RP6530
- Where
- 8 sites in United States
- Volunteers
- 58 people
- Sponsor
- Rhizen Pharmaceuticals SA
T Cell Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified
Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma
The purpose of this study is to test the safety and efficacy of AUTO4 a chimeric antigen receptor (CAR) T cell treatment targeting TRBC1 in patients with relapsed or refractory TRBC1 positive selected T-Non-Hodgkin Lymphoma (NHL).
- Conditions
- T Cell Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Anaplastic Large Cell Lymphoma
- Trial name
- NCT03590574
- Testing
- AUTO4
- Where
- 5 sites in Spain, United Kingdom
- Volunteers
- 20 people
- Sponsor
- Autolus Limited
Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma
Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma
The purpose of this study is to evaluate the objective response rate (ORR) of E7777 in participants with relapsed or refractory peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).
- Trial name
- NCT02676778
- Testing
- E7777
- Where
- 20 sites in Japan
- Volunteers
- 45 people
- Sponsor
- Eisai Co., Ltd.
Refractory Peripheral T-Cell Lymphoma, Relapsed T-Cell Lymphoma
A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL
This is a single arm, open-label, multi-center study designed to demonstrate the efficacy and safety of pralatrexate when administered concurrently with vitamin B12 and folic acid supplementation to patients with relapsed or…
- Trial name
- NCT03349333
- Testing
- pralatrexate, Vitamin B12 and folic acid
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Mundipharma (China) Pharmaceutical Co. Ltd
Lymphoma
A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma
Prospective, multicenter, phase II clinical trial to determine the efficacy of plitidepsin in patients with relapsed/refractory (R/R) angioimmunoblastic Tcell lymphoma (AITL).This is an international, multicenter study (with…
- Trial name
- NCT03070964
- Testing
- plitidepsin
- Where
- 17 sites in United States, Czechia and 2 more
- Volunteers
- 14 people
- Sponsor
- PharmaMar
Cutaneous T-Cell Lymphoma
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
The purpose of this study is to compare the progression free survival of KW-0761 versus vorinostat for subjects with relapsed or refractory CTCL.
- Trial name
- NCT01728805
- Testing
- KW-0761, Vorinostat
- Where
- 73 sites in United States, Australia and 9 more
- Volunteers
- 372 people
- Sponsor
- Kyowa Kirin, Inc.
Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
This is a phase 3, randomized, 2-arm, open-label, international trial evaluating alisertib compared with single-agent treatment, as selected by the investigator from the offered options of pralatrexate or gemcitabine or…
- Trial name
- NCT01482962
- Testing
- Alisertib, Pralatrexate, Gemcitabine
- Where
- 151 sites in United States, Australia and 29 more
- Volunteers
- 271 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Relapsed/Refractory Peripheral T-cell Lymphoma, Relapsed/Refractory Classical Hodgkins Lymphoma
AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL
This is a modular dose confirmation and expansion study. The core study design is to assess the efficacy of AZD4573, administered as monotherapy or combination therapy, to participants with either r/r PTCL or r/r cHL and to…
- Trial name
- NCT05140382
- Testing
- AZD4573
- Where
- 27 sites in United States, Australia and 6 more
- Volunteers
- 52 people
- Sponsor
- AstraZeneca
Effect of Drugs
Efficacy and Safety Evaluation of IBI308 in Patients With Extranodal NK/T Cell Lymphoma Patients
This is phase II study. Efficacy and safety evaluation of IBI308 in patients with relapsed/refractory extranodal NK/T cell lymphoma, nasal type: a multicenter, single arm.
- Trial name
- ORIENT-4 (NCT03228836)
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
T Cell Lymphoma
Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma
To characterize safety, tolerability and to establish the maximum tolerated dose (MTD) of Tenalisib in combination with Romidepsin in patients with R/R T-cell lymphoma.
- Trial name
- NCT03770000
- Testing
- Tenalisib, Romidepsin
- Where
- 15 sites in United States
- Volunteers
- 33 people
- Sponsor
- Rhizen Pharmaceuticals SA
Peripheral T-Cell Lymphoma (PTCL)
Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, efficacy, and pharmacokinetics of HBI-8000 40 mg BIW in patients with relapsed or refractory PTCL (R/R PTCL).
- Trial name
- NCT02953652
- Testing
- HBI-8000
- Where
- 23 sites in Japan, South Korea
- Volunteers
- 55 people
- Sponsor
- HUYABIO International, LLC.
Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL)
Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma
This is a single-arm, multi-center, open-label phase 2 study of the SINE™ compound selinexor given orally to patients with relapsed or refractory PTCL or CTCL.
- Trial name
- NCT02314247
- Testing
- Selinexor
- Where
- 5 sites in Australia, Singapore
- Volunteers
- 16 people
- Sponsor
- Karyopharm Therapeutics Inc
Relapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma
Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies
This study is for patients with lymphoproliferative malignancies that have progressed after receiving a previous treatment (relapsed) or are no longer responding to treatment (refractory).
- Conditions
- Relapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma, Peripheral T-cell Lymphoma, B-cell Lymphoma
- Trial name
- NCT00481871
- Testing
- Pralatrexate Injection, Gemcitabine Hydrochloride, Vitamin B12
- Where
- 15 sites in United States
- Volunteers
- 119 people
- Sponsor
- Acrotech Biopharma Inc.
Peripheral T Cell Lymphoma, PTCL
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
This was a multi-center, prospective, non-randomized, open-label, Phase 2 clinical study to evaluate the safety and efficacy of BGB-A317 in participants with relapsed or refractory mature T- and natural killer (NK)-cell…
- Conditions
- Peripheral T Cell Lymphoma, PTCL, Extranodal NK/T-cell Lymphoma, Extranodal NK/T-cell Lymphoma, Nasal Type
- Trial name
- NCT03493451
- Testing
- Tislelizumab
- Where
- 24 sites in Canada, China and 3 more
- Volunteers
- 77 people
- Sponsor
- BeiGene
Peripheral T Cell Lymphoma, Pediatric Hodgkin Lymphoma
Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma"
The purpose of this survey is to examine the safety of adult patients with relapsed or refractory CD30-positive peripheral T-cell lymphoma (PTCL) (excluding anaplastic large cell lymphoma (ALCL)) and pediatric patients with…
- Trial name
- NCT04213209
- Testing
- Brentuximab Vedotin (Genetical Recombination)
- Where
- Japan
- Volunteers
- 95 people
- Sponsor
- Takeda